Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
John W. Eikelboom, Jackie Bosch, Stuart J. Connolly, Jessica Tyrwitt, Keith A.A. Fox, Eva Muehlhofer, Christoph Neumann, Christoph Tasto, Shrikant I. Bangdiwala, Rafael Díaz, Marco Alings, Gilles R. Dagenais, Darryl P. Leong, Eva Lonn, Álvaro Avezum, Leopoldo Soares Piegas, Petr Widimský, Alexander Parkhomenko, Deepak L. Bhatt, Kelley R. Branch, Jeffrey L. Probstfield, Patricio López‐Jaramillo, Lars Rydén, Nana Pogosova, Katalin Keltai, Matyàs Keltai, Georg Ertl, Stefan Störk, Antonio L Dans, Fernando Laņas, Yan Liang, Jun Zhu, Christian Torp‐Pedersen, Aldo Maggioni, Patrick Commerford, Tomasz J. Guzik, Thomas Vanassche, Peter Verhamme, Martin O’Donnell, Andrew M. Tonkin, George Varigos, Dragoş Vinereanu, Camillo Felix, Jae‐Hyung Kim, Khairul Shafiq Ibrahim, Basil S. Lewis, Kaj Metsärinne, Victor Aboyans, Philippe Gabríel Steg, Masatsugu Hori, Ajay K. Kakkar, Sonia S. Anand, André Lamy, Mukul Sharma, Salim Yusuf (2022). Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. , 8(8), DOI: https://doi.org/10.1093/ehjcvp/pvac023.
